Aspen Neuroscience Announces Pricing of Initial Public Offering

SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson’s disease (PD), today announced the pricing of its initial public offering of 9,375,000 shares of common stock at a price to the public of $15.00 per share. All of the shares of common stock are being offered by Aspen. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Aspen, are expected to be approximately $140.6 million. In addition, Aspen has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less underwriting discounts and commissions.

The shares are expected to begin trading on The Nasdaq Global Select Market on October 30, 2026, under the ticker symbol “ASPE.” The offering is expected to close on November 2, 2026, subject to the satisfaction of customary closing conditions.